Vera Therapeutics Inc. Class A (VERA)
$36.82
$1.54
(4.37%)
As on 26-Aug-2026 16:00EDT
Market cap
$2,326 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-5.9
-
Face value
--
-
Shares outstanding
72,063,335
5 Years Aggregate
CFO
$-228.58 Mln
EBITDA
$-290.88 Mln
Net Profit
$-282.92 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
| -27.3 | 3.9 | 8.2 | 72.5 | 27.2 | 16.7 | -- |
|
BSE Sensex*
| -8.8 | 1.5 | 1.6 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
| 19.7 | 172.7 | -20.5 | -27.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
|
36.8 | 2,325.8 | 0.0 | -401.9 | -- | -79.4 | -- | 5.5 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 359.8 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Vera Therapeutics Inc. Class A (VERA)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion... protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Read more
-
Founder, President, CEO & Director
Dr. Marshall W. Fordyce M.D.
-
Founder, President, CEO & Director
Dr. Marshall W. Fordyce M.D.
-
Headquarters
Brisbane, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vera Therapeutics Inc. Class A (VERA)
What is the current share price of Vera Therapeutics Inc Class A (VERA) Today?
The share price of Vera Therapeutics Inc Class A (VERA) is $36.82 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Vera Therapeutics Inc Class A (VERA) has given a return of 27.15% in the last 3 years.
What is the current PB & PE ratio of Vera Therapeutics Inc Class A (VERA)?
Since, TTM earnings of Vera Therapeutics Inc Class A (VERA) is negative, P/E ratio is not available.
The P/B ratio of Vera Therapeutics Inc Class A (VERA) is 5.52 times as on 21-Aug-2026, a 3 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-10.86 |
5.38 |
2024 |
-15.26 |
4.02 |
2023 |
-7.12 |
6.72 |
2022 |
-6.04 |
6.99 |
2021 |
-17.43 |
8.17 |
What is the 52 Week High and Low of Vera Therapeutics Inc Class A (VERA)?
The 52-week high and low of Vera Therapeutics Inc Class A (VERA) are Rs 56.05 and Rs 21.15 as of 27-Aug-2026.
What is the market cap of Vera Therapeutics Inc Class A (VERA)?
Vera Therapeutics Inc Class A (VERA) has a market capitalisation of $ 2,326 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Vera Therapeutics Inc Class A (VERA)?
Before investing in Vera Therapeutics Inc Class A (VERA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.